이달의 증례

HOME

자료실
이달의 증례
Tachycardia induced Cardiomyopathy
년도 2019년 9월
카테고리 이달의 kcj Hot Article
저자 Do Young Kim, MD,1,* Sung Hea Kim, MD, PhD,2,* and Kyu-Hyung Ryu, MD, PhD3
소속 1Cardiovascular Center, Korea University Anam Hospital, Seoul, Korea. 2Division of Cardiology, Department of Medicine, Konkuk University Medical Center, Seoul, Korea. 3Department of Cardiology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.
첨부파일 1 kcj-49-e110-g001-l.jpg
  • 관리자
  • 등록일 : 2019.08.28
  • Hit 152
Abstract

Recent studies on radiofrequency catheter ablation (RFCA) in atrial fibrillation show its effectiveness in heart failure (HF) patients; hence, tachycardia-induced cardiomyopathy (T-CMP) is gaining attention. Tachycardia-mediated cardiomyopathy is a reversible left ventricular (LV) dysfunction, which can be induced by any tachyarrhythmia. Early recognition of T-CMP with appropriate treatment of the arrhythmia culprit will lead to the recovery of LV function. Patients with tachycardia and LV dysfunction should be suspected of having T-CMP, with or without established etiology of HF, because T-CMP may present by itself or contribute as a co-existent component. Therapeutic options include rate control, anti-arrhythmic drugs, or catheter ablation. Unlike in animal models, clinical data on human T-CMP is limited. Hence, future research should be more focused on tachyarrhythmia-induced cardiomyopathy as its burden is increasing.

Keywords:
Heart failure; Tachycardia; Cardiomyopathies
본문:

https://www.e-kcj.org/DOIx.php?id=10.4070/kcj.2019.0199

 

댓글 0